Accessibility settings

This paper is in the following e-collection/theme issue:

Non-Randomized Study Protocols and Methods (Non-eHealth) (1179) Adverse Drug Events Detection, Pharmacovigilance and Surveillance (258) Safety and Error Prevention in Health (309) Pharmacovigilance (238) Pharmacology and Pharmaceutics (158) Immunology, Allergy, Rheumatology (187)

Published on in Vol 14 (2025)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/70312, first published .
Woman using smartphone while holding medication blister pack

Therapeutic Drug Monitoring for Precision Dosing of Janus Kinase Inhibitors: Protocol for a Prospective Observational Study

Therapeutic Drug Monitoring for Precision Dosing of Janus Kinase Inhibitors: Protocol for a Prospective Observational Study

Authors of this article:

Jérémie Tachet1 Author Orcid Image ;   Laurent A Decosterd2 Author Orcid Image ;   Monia Guidi1, 3, 4 Author Orcid Image ;   François R Girardin1, 2 Author Orcid Image
Article Authors Cited by (2) Tweetations Metrics

Journals

  1. Tachet J, Marzolini C, Decosterd L, Guidi M, Girardin F. Therapeutic drug monitoring of Janus kinase inhibitors for precision dosing: where do we stand ?. Expert Review of Clinical Pharmacology 2025;18(10):753 View
  2. Tachet J, Meyer S, Grandoni F, Haefliger E, Nagy‐Hulliger M, Halter J, Passweg J, Haefliger D, Bardinet C, Decosterd L, Guidi M, Girardin F. Ruxolitinib Pharmacokinetics and Exposure–Toxicity Relationship in Hematologic Malignancies and Immune‐Mediated Diseases: A Prospective Observational Study. Clinical Pharmacology & Therapeutics 2026 View